Has China's State Council Decree No. 818 Really Made Cell Therapy Legally Billable? Five Critical Details to Understand Before Celebrating

1 Core Logic: After filing, the product can be commercialized; after commercialization, fees can be charged. However, its use is restricted to the originating hospital and external sales are prohibited.

Three mandatory access criteria: ① Grade A tertiary hospital status + GCP qualification; ② Senior professional title + GCP certificate; ③ The hospital’s legal representative serves as the filer and assumes unlimited liability.

Five Red Lines: Refund and fivefold penalty for irregular charges; fines of RMB 10 million or 20 times the illegal gains for data falsification; individual practice bans ranging from five years to lifetime; hospitals must compensate patients first before seeking recourse for health damages; national platform accepts reports 24/7. In short: extremely high thresholds, hefty fines, and severe liabilities.

1. Academic Review: Evidence of achieving preset endpoints must be published in top-tier journals in the field, and all raw data must be uploaded to the national system for peer scrutiny.

2. Ethical Oversight: The hospital’s ethics committee holds veto power and the authority to suspend activities at any time, while national medical ethics experts conduct random unannounced inspections.

3. Administrative Review: The provincial Health Commission completes a formal review of the “conversion permit” application within 15 working days. Note that this is strictly a formal review, not a scientific evaluation; however, the submitted materials are simultaneously forwarded to relevant institutions for blind spot checks. Any discrepancies or inflated claims will result in immediate suspension. The 15-day period does not constitute “approval,” but rather serves as a “countdown for spot checks.”

1. Blank spots in the technology list: Beyond somatic cells, gene editing, and tissue engineering, how are in vivo CAR therapies, AAV vectors, and personalized mRNA vaccines classified? The absence of clear classification criteria means there is a risk that filings submitted today could be reclassified and rejected tomorrow.

2. Blurred Boundaries of Innovation: Does codon optimization of CD19 CAR alone qualify as a “new technology”? If yes, the filing channels will be instantly overwhelmed by a homogeneous red ocean; if no, companies’ multi-million RMB investments in GMP manufacturing will go down the drain.

3. Absence of Endpoint Metrics: Safety and Efficacy ≠ Reimbursability. Who determines the surrogate endpoints, minimum sample size, and follow-up duration? Currently, the reference is 12 cases/24 weeks as per the “Guidelines for Somatic Cell Work (2021),” but Decree No. 818 does not lock these parameters in place, leaving them subject to overturning by new regulations at any time.

4. Uncertainty Regarding Data Interoperability: Will the Center for Drug Evaluation (CDE) accept the electronic health records (EHR), pharmacokinetic (PK), and immunogenicity data generated during the filing process? If not, duplicate trials will be required, doubling the costs; if accepted, compliance with both Good Laboratory Practice (GLP) and Good Clinical Practice (GCP) dual audits is mandatory. Are hospitals willing to provide access to original records?

5. Risks of Retroactive Audits: For Investigator-Initiated Trials (IITs) conducted between 2015 and 2025 to be regularized, it is mandatory to submit supplementary documentation, including ethics committee approval letters, original records of Serious Adverse Events (SAEs), and proof of subject compensation. The absence of any single item constitutes a compliance violation. The statute of limitations for retrospective review is five years from the conclusion of the trial. Many institutions have failed to retain even PDF copies of these documents, making traceability impossible.

1. Gray-market stem cell clinics: Those that previously collected RMB 600,000 for cell infusion services under the guise of “health management” now lack accreditation from Grade A tertiary hospitals and face penalties including “refund plus fivefold compensation” as well as fines up to 20 times the illegal gains. A cash flow breakdown is only a matter of time, with more than 90% expected to exit the market within one year.

2. Non-tier-3 hospitals: Secondary hospitals and high-end clinics have lost their home-field advantage in clinical trials. Existing projects are either terminated or incur significantly higher costs by partnering with tier-3 hospitals through “shell” arrangements, leading to a sharp rise in expenses and customer attrition.

3. Innovative Pharmaceutical Companies: If the filing approval process is liberalized too rapidly, allowing hospitals to charge for “Phase 0” trials, why would patients wait for Phase III results? The economic incentive for companies to continue advancing Investigational New Drug (IND) applications would be weakened. Pipelines already in Phase I/II would need to recalculate their market exclusivity periods, capital valuation models would have to incorporate a new “filing-based diversion” scenario, and financing would become more difficult.

4. CRO/CDMO: Regulatory filings now permit hospitals to establish closed, bedside point-of-care preparation systems, reducing demand for external central manufacturing facilities. Traditional clinical CRO services—including monitoring, biostatistics, and medical writing—are facing pressure from decentralization trends. Consequently, service models are being forced to pivot toward “regulatory filing consultation, quality control, and registration bridging,” resulting in declines in both unit prices and gross profit margins.

5. Boao Lecheng: The greatest advantage of the Pilot Zone is its “fee-charging franchise.” Once all Grade A tertiary hospitals across China are permitted to convert and charge for treatments under Order No. 818, without requiring registration for imported drugs and medical devices, why would domestic patients still need to travel to Hainan? Will the traffic dividend enjoyed by Lecheng be rapidly diluted? Will upgrading differentiated services be prioritized on the agenda soon?

1. Immediately initiate data traceability: Electronically archive raw records, ethics approvals, SAE reports, and subject compensation vouchers since 2018 in compliance with 21 CFR Part 11 standards. It is preferable to proactively terminate projects with missing documentation rather than leave vulnerabilities.

2. Establish a dual-channel quality system: A single set of SOPs simultaneously meets GCP and filing requirements, integrating the four data streams—electronic medical records, sample chain, drug chain, and imaging chain—to ensure seamless adaptation during future spot checks by the CDE.

3. Secure adequate liability insurance: Purchase coverage with dual caps based on the “maximum compensation for human subject trials plus 20 times the fine,” and list the hospital, sponsor, and CRO as co-insured parties to prevent personal assets from being pursued in the event of an incident.

Decree No. 818 indeed establishes, for the first time at the national level, a compliant pathway for cell and gene therapies encompassing “filing–translation–charging.” However, “being permitted to charge fees” does not equate to “immediate profitability.”

With the five supporting documents—namely, the technical checklist, innovation standards, endpoint metrics, mutual recognition of data, and resolution of legacy issues—yet to be implemented, anyone prematurely touting that “a 100,000-yuan-per-dose treatment is now legal” is either foolish or malicious.

Policy dividends will only accrue to those players with robust GCP compliance, complete data sets, adequate insurance coverage, and the agility to switch seamlessly between the filing and registration pathways. Refrain from premature celebration; focus on solidifying your operational foundation. It is not too late to accelerate once the other shoe drops.

(By Xiao Shengke)